γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity
Blood Cells, Molecules, and Diseases · 2023
DOI: 10.1016/j.bcmd.2023.102746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Cells, Molecules, and Diseases, 2023. Verfasst von Lucy Z Kornblith und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California, San Francisco, CA, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID-19) is characterized by a pro-inflammatory state associated with organ failure, thrombosis, and death. We investigated a novel inflammatory biomarker, γ' fibrinogen (GPF), in 103 hospitalized patients with COVID-19 and 19 healthy controls. We found significant associations between GPF levels and the severity of COVID-19 as judged by blood oxygen saturation (SpO2). The mean level of GPF in the patients with COVID-19 was significantly higher than in controls (69.8 (95 % CI 64.8-74.8) mg/dL compared with 36.9 (95 % CI 31.4-42.4) mg/dL, p 93 %, GPF 62.5 (95 % CI 55.0-70.0) mg/dL, p = 0.01, AUC of 0.68, 95 % CI 0.57-0.78; Youden's index cutpoint 62.9 mg/dL, sensitivity 0.64, specificity 0.63). In contrast, CRP, interleukin-6, ferritin, LDH, D-dimers, and total fibrinogen had weaker associations with COVID-19 disease severity (all ROC curves with lower AUCs). Thus, GPF may be a useful inflammatory marker of COVID-19 respiratory disease severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of California, San Francisco, CA, USA.
- Theragen Biologics Pvt Ltd, Chennai, India.
- Fiona Stanley Fremantle Hospital Group, Murdoch, Western Australia, Australia; Edith Cowan University, Joondalup, Western Australia, Australia.
- Department of Surgery, Oregon Health & Science University, Portland, OR, USA.
- Gamma Diagnostics, Portland, OR, USA.
- MagGenome Pvt Ltd, Chennai, India.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Kornblith, L. Z., Sadhanandhan, B., Arun, S., Long, R., Johnson, A. J., Noll, J., Ramchand, C. N., Olynyk, J. K., & Farrell, D. H. (2023). γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity. Blood Cells, Molecules, and Diseases. https://doi.org/10.1016/j.bcmd.2023.102746
Vancouver
Kornblith LZ, Sadhanandhan B, Arun S, Long R, Johnson AJ, Noll J, et al. γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity. Blood Cells, Molecules, and Diseases. 2023. doi:10.1016/j.bcmd.2023.102746
BibTeX
@article{Kornblith2023,
author = {Kornblith, Lucy Z and Sadhanandhan, Bindhya and Arun, Sreepriya and Long, Rebecca and Johnson, Alicia J and Noll, Jamie and Ramchand, C N and Olynyk, John K and Farrell, David H},
title = {γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity},
journal = {Blood Cells, Molecules, and Diseases},
year = {2023},
doi = {10.1016/j.bcmd.2023.102746}
}
EUVIMED